Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of pegylated interferon alpha in treating postpartum women with chronic hepatitis B virus infection: a multicenter prospective study.

Frontiers in cellular and infection microbiology·2026
Same author

A lightweight improved YOLOv8 method for intelligent detection of pine wilt disease.

Scientific reports·2025
Same author

Polarization-Driven Energy Storage Enhancement in KNN-Based Relaxor Ceramics under Moderate Electric Field.

Small (Weinheim an der Bergstrasse, Germany)·2025
Same author

More aggressive initiation of antiviral treatment contributes to blocking mother-to-child transmission of HBV DNA & RNA in neonatal umbilical cord blood.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2025
Same author

Knowledge, attitudes, and practices toward fatty liver disease in patients with hepatitis B combined fatty liver disease.

Scientific reports·2025
Same author

Discovery of a Novel Series of <i>iso</i>-Indolinone-Based Glutarimides as Highly Efficacious and Selective IKZF2 Molecular Glue Degraders.

Journal of medicinal chemistry·2025

Related Experiment Video

Updated: Jun 3, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

Electron density guided fragment-based drug design--a lead generation example.

Marta C Abad1, Alan C Gibbs, Xuqing Zhang

  • 1Structural Biology and Medicinal Chemistry, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Spring House, Pennsylvania, USA.

Methods in Enzymology
|March 5, 2011
PubMed
Summary
This summary is machine-generated.

This study introduces a novel protein crystallography method for fragment-based lead discovery. This approach bypasses traditional solution assays, yielding drug-like leads efficiently.

More Related Videos

NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode
09:19

NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode

Published on: June 4, 2021

Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin
06:29

Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin

Published on: March 3, 2021

Related Experiment Videos

Last Updated: Jun 3, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode
09:19

NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode

Published on: June 4, 2021

Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin
06:29

Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin

Published on: March 3, 2021

Area of Science:

  • Biochemistry
  • Structural Biology
  • Drug Discovery

Background:

  • Fragment-based drug design (FBDD) traditionally relies on biophysical screening methods.
  • Protein crystallography offers high-resolution structural information crucial for understanding ligand-target interactions.
  • An integrated crystallographic approach can streamline lead discovery by directly visualizing binding events.

Purpose of the Study:

  • To present a refined fragment-based drug discovery methodology utilizing protein crystallography as the sole detection technique.
  • To demonstrate the efficacy of iterative compound design and X-ray screening for identifying novel lead compounds.
  • To showcase an alternative FBDD strategy that minimizes reliance on solution-based activity assays.

Main Methods:

  • Iterative design, synthesis, and X-ray crystallographic screening of three compound libraries.
  • Utilizing active site electron density from bound fragment hits to guide subsequent compound design.
  • Employing a strategy that intentionally omits solution activity bias during the initial screening phases.

Main Results:

  • Successful application of the crystallographic-only screening method.
  • Generation of a unique lead series against the target ketohexokinase.
  • The identified lead series exhibited promising drug-like properties.

Conclusions:

  • Protein crystallography can serve as a singular detection tool in fragment-based lead discovery.
  • This method enables target-specific compound design based on direct structural evidence.
  • The presented approach offers an efficient alternative for identifying novel drug leads with favorable characteristics.